A study of circulating microRNAs identifies a new potential biomarker panel to distinguish aggressive prostate cancer
Open Access
- 17 February 2018
- journal article
- research article
- Published by Oxford University Press (OUP) in Carcinogenesis
- Vol. 39 (4) , 556-561
Abstract
Prostate cancer is one of the most common cancers in men worldwide. Currently available diagnostic and prognostic tools for this disease, such as prostate specific antigen, suffer from lack of specificity and sensitivity, resulting in over- and misdiagnosis. Hence, there is an urgent need for clinically relevant biomarkers capable of distinguishing between aggressive and nonaggressive forms of prostate cancer to aid in stratification, management and therapeutic decisions. To address this unmet need, we investigated the patterns of expression of a panel of 68 plasma-derived microRNAs (miRNAs) in a cohort of African American (AA) and European American (EA) prostate cancer patients (n = 114). miRNA qPCR results were analyzed using in-depth statistical methods, and a bioinformatics analysis was conducted to identify potential targets of the differentially expressed miRNAs. Our data demonstrate that a new previously unreported circulating miRNA signature consisting of a combination of interacting miRNAs (miR-17/miR-192) and an independent miRNA (miR-181a) are capable of segregating aggressive and nonaggressive prostate cancer in both AA and EA patients. The interacting miRNAs outperformed independent miRNAs in identifying aggressiveness. Our results suggest that these circulating miRNAs may constitute novel biomarkers of prostate cancer aggressiveness in both races and warrant further investigation.Keywords
Funding Information
- NIH
This publication has 33 references indexed in Scilit:
- MicroRNA-20a Constrains p300-Driven Myocardial Angiogenic Transcription by Direct Targeting of p300PLOS ONE, 2013
- Changes in circulating microRNA levels associated with prostate cancerBritish Journal of Cancer, 2012
- Tumorigenicity of the miR-17-92 cluster distilled: Figure 1.Genes & Development, 2010
- Coordinated Regulation of Cell Cycle Transcripts by p53-Inducible microRNAs, miR-192 and miR-215Cancer Research, 2008
- Multivariate gene expression analysis reveals functional connectivity changes between normal/tumoral prostatesBMC Systems Biology, 2008
- Circulating microRNAs as stable blood-based markers for cancer detectionProceedings of the National Academy of Sciences of the United States of America, 2008
- p300 (histone acetyltransferase) biomarker predicts prostate cancer biochemical recurrence and correlates with changes in epithelia nuclear size and shapeThe Prostate, 2008
- The transcriptional coactivator and acetyltransferase p300 in fibroblast biology and fibrosisJournal of Cellular Physiology, 2007
- MicroRNA Signatures in Human CancersNature Reviews Cancer, 2006
- Identification and Characterization of a Novel Gene, C13orf25 , as a Target for 13q31-q32 Amplification in Malignant LymphomaCancer Research, 2004